11.91
price up icon0.68%   0.08
pre-market  プレマーケット:  12.09   0.18   +1.51%
loading
前日終値:
$11.83
開ける:
$11.83
24時間の取引高:
2.36M
Relative Volume:
0.44
時価総額:
$1.67B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-3.1124
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
-0.25%
1か月 パフォーマンス:
-10.45%
6か月 パフォーマンス:
+0.34%
1年 パフォーマンス:
+9.27%
1日の値動き範囲:
Value
$11.41
$12.04
1週間の範囲:
Value
$11.41
$12.31
52週間の値動き範囲:
Value
$7.95
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1079)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
11.91 1.69B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.75 133.25B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
803.48 82.16B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
851.29 54.80B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
203.71 43.99B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
347.48 40.62B 5.76B 514.49M 1.10B 4.4813

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Aug 15, 2026

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080 - TradingKey

Aug 15, 2026
pulisher
Aug 15, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Aug 15, 2026
pulisher
Aug 15, 2026

Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits

Aug 15, 2026
pulisher
Aug 13, 2026

Intellia (NTLA) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 13, 2026
pulisher
Aug 13, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Aug 13, 2026
pulisher
Aug 13, 2026

Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Aug 13, 2026
pulisher
Aug 12, 2026

Intellia Therapeutics Stock Short Interest Falls to 39.57% - Quiver Quantitative

Aug 12, 2026
pulisher
Aug 12, 2026

Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada - MarketBeat

Aug 12, 2026
pulisher
Aug 11, 2026

(NTLA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Aug 11, 2026
pulisher
Aug 11, 2026

Research Analysts Offer Predictions for NTLA FY2026 Earnings - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Intellia Therapeutics Insider Buyers See Boost After Market Cap Rose US$168m - Moomoo

Aug 10, 2026
pulisher
Aug 10, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st

Aug 10, 2026
pulisher
Aug 10, 2026

Equities Analysts Issue Forecasts for NTLA Q2 Earnings - MarketBeat

Aug 10, 2026
pulisher
Aug 08, 2026

Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results - MarketBeat

Aug 08, 2026
pulisher
Aug 08, 2026

Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail

Aug 08, 2026
pulisher
Aug 08, 2026

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 08, 2026
pulisher
Aug 08, 2026

Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment - Sahm

Aug 08, 2026
pulisher
Aug 08, 2026

NTLA SWOT Analysis: Financial Resilience Amidst Clinical Advancements Revealed in 10-Q Filing - GuruFocus

Aug 08, 2026
pulisher
Aug 07, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia Therapeutics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing - Stock Titan

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ) - Seeking Alpha

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations - DirectorsTalk Interviews

Aug 07, 2026
pulisher
Aug 07, 2026

Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative? - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

Intellia Therapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 07, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... By GuruFocus - Investing.com Canada

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics 2Q 2026: Revenue $7.7M, Net loss $106.6M, EPS $(0.80) — 10-Q Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlig - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings call transcript: Intellia posts Q2 2026 revenue miss as shares slip premarket - Investing.com

Aug 06, 2026
pulisher
Aug 06, 2026

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating - marketscreener.com

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Inc earnings matched, revenue fell short of estimates - Investing.com

Aug 06, 2026
pulisher
Aug 06, 2026

INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M - Moomoo

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia Therapeutics Q2 Operating Expenses U - moomoo.com

Aug 06, 2026
pulisher
Aug 06, 2026

Intellia plans first-half 2027 U.S. launch if FDA approves hereditary angioedema treatment - Stock Titan

Aug 06, 2026
pulisher
Aug 05, 2026

Dimensional Fund Advisors LP Increases Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Aug 05, 2026
pulisher
Aug 03, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 03, 2026
pulisher
Jul 31, 2026

Arrowstreet Capital Limited Partnership Makes New Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Jul 31, 2026
pulisher
Jul 30, 2026

Intellia Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 6 - moomoo.com

Jul 30, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$63.32
price down icon 0.52%
$58.60
price up icon 0.07%
$36.20
price down icon 0.22%
$123.74
price down icon 2.05%
$228.65
price up icon 0.67%
ONC ONC
$347.48
price down icon 2.40%
大文字化:     |  ボリューム (24 時間):